These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16182402)

  • 1. First report on the efficacy of l-alanine-based in situ-forming implants for the long-term parenteral delivery of drugs.
    Plourde F; Motulsky A; Couffin-Hoarau AC; Hoarau D; Ong H; Leroux JC
    J Control Release; 2005 Nov; 108(2-3):433-41. PubMed ID: 16182402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization and biocompatibility of organogels based on L-alanine for parenteral drug delivery implants.
    Motulsky A; Lafleur M; Couffin-Hoarau AC; Hoarau D; Boury F; Benoit JP; Leroux JC
    Biomaterials; 2005 Nov; 26(31):6242-53. PubMed ID: 15916802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
    Cox MC; Scripture CD; Figg WD
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):605-11. PubMed ID: 16111462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS; Pacificar JS; Shapiro CE; Williams SG
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase-sensitive polymer-based controlled delivery systems of leuprolide acetate: in vitro release, biocompatibility, and in vivo absorption in rabbits.
    Singh S; Singh J
    Int J Pharm; 2007 Jan; 328(1):42-8. PubMed ID: 16959451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stability of poly(D,L-lactide-co-glycolide) and leuprolide acetate in in-situ forming drug delivery systems.
    Dong WY; Körber M; López Esguerra V; Bodmeier R
    J Control Release; 2006 Oct; 115(2):158-67. PubMed ID: 16963145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulation and evaluation of an in situ gel forming system for controlled delivery of triptorelin acetate.
    Abashzadeh Sh; Dinarvand R; Sharifzadeh M; Hassanzadeh G; Amini M; Atyabi F
    Eur J Pharm Sci; 2011 Nov; 44(4):514-21. PubMed ID: 21946260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained suppression of pituitary-gonadal axis with an injectable, in situ forming implant of leuprolide acetate.
    Ravivarapu HB; Moyer KL; Dunn RL
    J Pharm Sci; 2000 Jun; 89(6):732-41. PubMed ID: 10824131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decrease of genital organ weights and plasma testosterone levels in rats following oral administration of leuprolide microemulsion.
    Zheng JY; Fulu MY
    Int J Pharm; 2006 Jan; 307(2):209-15. PubMed ID: 16300912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained activity and release of leuprolide acetate from an in situ forming polymeric implant.
    Ravivarapu HB; Moyer KL; Dunn RL
    AAPS PharmSciTech; 2000 Feb; 1(1):E1. PubMed ID: 14727850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure formation and characterization of injectable drug loaded biodegradable devices: in situ implants versus in situ microparticles.
    Kranz H; Bodmeier R
    Eur J Pharm Sci; 2008 Jul; 34(2-3):164-72. PubMed ID: 18501569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Organogels in drug delivery.
    Murdan S
    Expert Opin Drug Deliv; 2005 May; 2(3):489-505. PubMed ID: 16296770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In situ forming parenteral drug delivery systems: an overview.
    Packhaeuser CB; Schnieders J; Oster CG; Kissel T
    Eur J Pharm Biopharm; 2004 Sep; 58(2):445-55. PubMed ID: 15296966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer.
    Crawford ED; Sartor O; Chu F; Perez R; Karlin G; Garrett JS
    J Urol; 2006 Feb; 175(2):533-6. PubMed ID: 16406989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new injectable liquid crystal system for one month delivery of leuprolide.
    Ki MH; Lim JL; Ko JY; Park SH; Kim JE; Cho HJ; Park ES; Kim DD
    J Control Release; 2014 Jul; 185():62-70. PubMed ID: 24794897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo evaluation and in vitro metabolism of leuprolide in mice--mass spectrometry-based biomarker measurement for efficacy and toxicity.
    Sofianos ZD; Katsila T; Kostomitsopoulos N; Balafas V; Matsoukas J; Tselios T; Tamvakopoulos C
    J Mass Spectrom; 2008 Oct; 43(10):1381-92. PubMed ID: 18438975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics of depot leuprorelin.
    Periti P; Mazzei T; Mini E
    Clin Pharmacokinet; 2002; 41(7):485-504. PubMed ID: 12083977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In situ-forming pharmaceutical organogels based on the self-assembly of L-alanine derivatives.
    Couffin-Hoarau AC; Motulsky A; Delmas P; Leroux JC
    Pharm Res; 2004 Mar; 21(3):454-7. PubMed ID: 15070096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, Characterization and Biocompatibility of N-palmitoyl L-alanine-based Organogels as Sustained Implants of Granisetron and Evaluation of thier Antiemetic Effect.
    El-Nassan HB; ElMeshad AN; Wadie W; Sayed RH
    Pharm Res; 2018 May; 35(8):149. PubMed ID: 29845459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.